Drug Approval | January 05, 2026
FDA nod to first-ever treatment for deadly post-transplant complication TA-TMA
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
NUFYMCO BLA has been approved by the USFDA
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
